Le 2013 Thesis Colorado State University - Fort Collins: Difference between revisions

From Bioblast
(Created page with "{{Publication |title=Le CH (2013) Influence of cardiolipin remodeling on mitochondrial respiratory function in the heart. Thesis Colorado State University - Fort Collins 89pp. |...")
ย 
No edit summary
ย 
(4 intermediate revisions by 3 users not shown)
Line 1: Line 1:
{{Publication
{{Publication
|title=Le CH (2013) Influence of cardiolipin remodeling on mitochondrial respiratory function in the heart. Thesis Colorado State University - Fort Collins 89pp. ย 
|title=Le CH (2013) Influence of cardiolipin remodeling on mitochondrial respiratory function in the heart. Thesis Colorado State University - Fort Collins:89 pp.
|info=[http://digitool.library.colostate.edu/exlibris/dtl/d3_1/apache_media/L2V4bGlicmlzL2R0bC9kM18xL2FwYWNoZV9tZWRpYS8yNDYyOTI=.pdf pdf] ย 
|info=[http://digitool.library.colostate.edu/exlibris/dtl/d3_1/apache_media/L2V4bGlicmlzL2R0bC9kM18xL2FwYWNoZV9tZWRpYS8yNDYyOTI=.pdf pdf]
|authors=Le CH
|authors=Le CH
|year=2013
|year=2013
|journal=Thesis Colorado State University - Fort Collins
|journal=Thesis Colorado State University - Fort Collins
|abstract=The following investigation comprises a series of experiments with the overall aim of
|abstract=The following investigation comprises a series of experiments with the overall aim of elucidating the role of cardiolipin acyl-chain remodeling on mitochondrial respiratory function in the mammalian heart. The experiments tested the general hypothesis that changes in the fatty acid composition of cardiolipin, a unique mitochondrial phospholipid, contribute to cardiac
elucidating the role of cardiolipin acyl-chain remodeling on mitochondrial respiratory function in
mitochondrial respiratory dysfunction, which is believed to be an underlying mechanism of myocardial hypertrophy and contractile dysfunction in several cardiac pathologies. The specific aims of each experimental series were to: 1) Determine the influence of cardiolipin compositional changes on cardiac mitochondrial respiratory function in models of aging, pressure overload hypertrophy and heart failure, and 2) Determine how defects in the cardiolipin
the mammalian heart. The experiments tested the general hypothesis that changes in the fatty
remodeling process itself elicits cardiac mitochondrial respiratory dysfunction associated with a genetic childhood-onset cardiomyopathy, known as Barth syndrome. Studies in Aim 1 demonstrated that the distinct pattern of aberrant cardiolipin remodeling observed in the aged and failing heart resulted from increased metabolism of polyunsaturated fatty acids (PUFAs), which predominate in the cardiolipin molecular species. Pharmacological inhibition of delta-6
acid composition of cardiolipin, a unique mitochondrial phospholipid, contribute to cardiac
desaturase, the rate-limiting enzyme in the PUFA metabolism pathway, reversed cardiolipin remodeling, reduced myocardial hypertrophy and preserved contractile function in the rodent models of aging, pressure overload and hypertensive heart disease. However, in contrast to our hypothesis, reversal of these changes in cardiolipin composition did not have a significant effect
mitochondrial respiratory dysfunction, which is believed to be an underlying mechanism of
on mitochondrial respiratory function, dissociating alterations in cardiolipin composition from cardiac mitochondrial respiratory dysfunction in these conditions. Studies in Aim 2 demonstrated a marked substrate-specific impairment of cardiac mitochondrial respiratory function in mice lacking the cardiolipin remodeling enzyme, tafazzin. Cardiac mitochondria from tafazzindeficient mice demonstrated a selective impairment in carbohydrate and lipid oxidation and a dramatic decrease in pantothenic acid amounts. These data suggest a role of tafazzin in the transport, activation, and/or generation of reducing equivalents by the TCA cycle. Additionally, these data implicate impairment of tafazzin function and/or cardiolipin remodeling process itself,
myocardial hypertrophy and contractile dysfunction in several cardiac pathologies. The specific
rather than alter cardiolipin composition per se, in mitochondrial dysfunction associated in Barth syndrome. Collectively, these findings challenge previous studies suggesting that alterations of the distinctly uniform acyl-chain composition of cardiolipin impair cardiac mitochondrial respiration. Rather, they instead show that the widely observed redistribution of cardiolipin
aims of each experimental series were to: 1) Determine the influence of cardiolipin
PUFA content in chronic cardiac pathologies appears to reflect a global increase in PUFA metabolism that profoundly influences cardiac structure and function by mechanisms we are only beginning to understand. Interestingly, the cardiolipin remodeling process itself and/or tafazzin enzyme may play a more important role than previously thought in cardiac mitochondrial respiratory function and cardiomyopathy.
compositional changes on cardiac mitochondrial respiratory function in models of aging,
pressure overload hypertrophy and heart failure, and 2) Determine how defects in the cardiolipin
remodeling process itself elicits cardiac mitochondrial respiratory dysfunction associated with a
genetic childhood-onset cardiomyopathy, known as Barth syndrome. Studies in Aim 1
demonstrated that the distinct pattern of aberrant cardiolipin remodeling observed in the aged
and failing heart resulted from increased metabolism of polyunsaturated fatty acids (PUFAs),
which predominate in the cardiolipin molecular species. Pharmacological inhibition of delta-6
desaturase, the rate-limiting enzyme in the PUFA metabolism pathway, reversed cardiolipin
remodeling, reduced myocardial hypertrophy and preserved contractile function in the rodent
models of aging, pressure overload and hypertensive heart disease. However, in contrast to our
hypothesis, reversal of these changes in cardiolipin composition did not have a significant effect
on mitochondrial respiratory function, dissociating alterations in cardiolipin composition from
cardiac mitochondrial respiratory dysfunction in these conditions. Studies in Aim 2 demonstrated
a marked substrate-specific impairment of cardiac mitochondrial respiratory function in mice
lacking the cardiolipin remodeling enzyme, tafazzin. Cardiac mitochondria from tafazzindeficient
mice demonstrated a selective impairment in carbohydrate and lipid oxidation and a
dramatic decrease in pantothenic acid amounts. These data suggest a role of tafazzin in the
transport, activation, and/or generation of reducing equivalents by the TCA cycle. Additionally,
these data implicate impairment of tafazzin function and/or cardiolipin remodeling process itself,
rather than alter cardiolipin composition per se, in mitochondrial dysfunction associated in Barth
syndrome. Collectively, these findings challenge previous studies suggesting that alterations of
the distinctly uniform acyl-chain composition of cardiolipin impair cardiac mitochondrial
respiration. Rather, they instead show that the widely observed redistribution of cardiolipin
PUFA content in chronic cardiac pathologies appears to reflect a global increase in PUFA
metabolism that profoundly influences cardiac structure and function by mechanisms we are only
beginning to understand. Interestingly, the cardiolipin remodeling process itself and/or tafazzin
enzyme may play a more important role than previously thought in cardiac mitochondrial
respiratory function and cardiomyopathy.
}}
}}
{{Labeling
{{Labeling
|additional=Labels
|area=Respiration, mt-Medicine
|organism=Mouse
|tissues=Heart
|preparations=Isolated mitochondria
|couplingstates=LEAK, OXPHOS
|pathways=N, S
|instruments=Oxygraph-2k
}}
}}

Latest revision as of 09:13, 8 November 2016

Publications in the MiPMap
Le CH (2013) Influence of cardiolipin remodeling on mitochondrial respiratory function in the heart. Thesis Colorado State University - Fort Collins:89 pp.

ยป pdf

Le CH (2013) Thesis Colorado State University - Fort Collins

Abstract: The following investigation comprises a series of experiments with the overall aim of elucidating the role of cardiolipin acyl-chain remodeling on mitochondrial respiratory function in the mammalian heart. The experiments tested the general hypothesis that changes in the fatty acid composition of cardiolipin, a unique mitochondrial phospholipid, contribute to cardiac mitochondrial respiratory dysfunction, which is believed to be an underlying mechanism of myocardial hypertrophy and contractile dysfunction in several cardiac pathologies. The specific aims of each experimental series were to: 1) Determine the influence of cardiolipin compositional changes on cardiac mitochondrial respiratory function in models of aging, pressure overload hypertrophy and heart failure, and 2) Determine how defects in the cardiolipin remodeling process itself elicits cardiac mitochondrial respiratory dysfunction associated with a genetic childhood-onset cardiomyopathy, known as Barth syndrome. Studies in Aim 1 demonstrated that the distinct pattern of aberrant cardiolipin remodeling observed in the aged and failing heart resulted from increased metabolism of polyunsaturated fatty acids (PUFAs), which predominate in the cardiolipin molecular species. Pharmacological inhibition of delta-6 desaturase, the rate-limiting enzyme in the PUFA metabolism pathway, reversed cardiolipin remodeling, reduced myocardial hypertrophy and preserved contractile function in the rodent models of aging, pressure overload and hypertensive heart disease. However, in contrast to our hypothesis, reversal of these changes in cardiolipin composition did not have a significant effect on mitochondrial respiratory function, dissociating alterations in cardiolipin composition from cardiac mitochondrial respiratory dysfunction in these conditions. Studies in Aim 2 demonstrated a marked substrate-specific impairment of cardiac mitochondrial respiratory function in mice lacking the cardiolipin remodeling enzyme, tafazzin. Cardiac mitochondria from tafazzindeficient mice demonstrated a selective impairment in carbohydrate and lipid oxidation and a dramatic decrease in pantothenic acid amounts. These data suggest a role of tafazzin in the transport, activation, and/or generation of reducing equivalents by the TCA cycle. Additionally, these data implicate impairment of tafazzin function and/or cardiolipin remodeling process itself, rather than alter cardiolipin composition per se, in mitochondrial dysfunction associated in Barth syndrome. Collectively, these findings challenge previous studies suggesting that alterations of the distinctly uniform acyl-chain composition of cardiolipin impair cardiac mitochondrial respiration. Rather, they instead show that the widely observed redistribution of cardiolipin PUFA content in chronic cardiac pathologies appears to reflect a global increase in PUFA metabolism that profoundly influences cardiac structure and function by mechanisms we are only beginning to understand. Interestingly, the cardiolipin remodeling process itself and/or tafazzin enzyme may play a more important role than previously thought in cardiac mitochondrial respiratory function and cardiomyopathy.


Labels: MiParea: Respiration, mt-Medicine 


Organism: Mouse  Tissue;cell: Heart  Preparation: Isolated mitochondria 


Coupling state: LEAK, OXPHOS  Pathway: N, S  HRR: Oxygraph-2k 


Cookies help us deliver our services. By using our services, you agree to our use of cookies.